These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 2149052

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
    Menichetti F, Martino P, Bucaneve G, Gentile G, D'Antonio D, Liso V, Ricci P, Nosari AM, Buelli M, Carotenuto M.
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
    [Abstract] [Full Text] [Related]

  • 8. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
    Nucci M, Biasoli I, Braggio S, Portugal R, Schaffel R, Maiolino A, Loureiro MM, Spector N, Pulcheri W.
    Oncol Rep; 1998 Sep; 5(5):1205-9. PubMed ID: 9683836
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia.
    Meunier F, Van der Auwera P, Aoun M, Bron D.
    Br J Haematol; 1990 Dec; 76 Suppl 2():49-53. PubMed ID: 2149053
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, Moreau P, Ladeb S, Nalet V, Rollin C, Gres JJ.
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC, Chiu HH, Tseng YC, Wang JH, Lin HC, Tsai FJ, Peng CT.
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [Abstract] [Full Text] [Related]

  • 17. Prophylaxis, cost and effectiveness of therapy of infections caused by gram-positive organisms in neutropenic children.
    Schaison GS, Decroly FC.
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():61-7. PubMed ID: 1829078
    [Abstract] [Full Text] [Related]

  • 18. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S, Raccah R, Santilli S, Micozzi A, Girmena C, Martino P, Avvisati G.
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever.
    Engervall P, Günther G, Ljungman P, Lönnqvist B, Hast R, Stiernstedt G, Kalin M, Ringertz S, Bjökholm M.
    Scand J Infect Dis; 1996 Oct; 28(3):297-303. PubMed ID: 8863366
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.